Suppr超能文献

结合熊果酸通过胰岛素分泌和糖原储存减轻链脲佐菌素诱导的糖尿病。

Combined with Ursolic Acid Attenuates Streptozotocin-Induced Diabetes through Insulin Secretion and Glycogen Storage.

机构信息

Department of Pharmacology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.

Health Information Technology Department, Faculty of Applied Studies, King Abdulaziz University, Jeddah -21589, Saudi Arabia.

出版信息

Oxid Med Cell Longev. 2020 Feb 18;2020:8565760. doi: 10.1155/2020/8565760. eCollection 2020.

Abstract

() and ursolic acid (UA) are ayurvedic medicines with multiple pharmacological activities including antidiabetic activity, but till date, no study is available on their combination. This study documented the antidiabetic efficacy of the combination of and UA in rats. Rats were divided into six groups. All groups were given a single dose of Streptozotocin (STZ) at a dose of 50 mg/kg by intraperitoneal route for induction of diabetes, except the normal control group. Group 1 was treated as a normal control (NC) group and fed with saline water, Group 2 as a Diabetes Control group, Group 3 as a STZ+ ethanolic extract (CREE) group at 50 mg/kg p.o., Group 4 as a STZ+UA group orally at 50 mg/kg, Group 5 as a STZ+CREE (25 mg/kg p.o.)+UA (25 mg/kg p.o.) group, and Group 6 as a STZ+Glimepiride (0.1 mg/kg) group. Diabetes was confirmed after 72 hours by estimation of blood glucose level, and then treatment was given for the next 28 days. During the course of treatment, plasma insulin and blood glucose were measured regularly at the interval of 7 days. At the end of the protocol, blood was collected and animals were sacrificed. The glucose level, insulin level, liver glycogen storage level, and antioxidant enzymes (LPO, CAT, SOD, GPx, GST) were measured. The blood glucose level in Group 5 significantly ( < 0.001) reduced to 98.35 ± 2.45 mg/dl in comparison with that in Group 2 (321.75 ± 5.46 mg/dl). The level of plasma insulin in Group 5 increased (13.65 ± 0.10 U/ml) significantly ( < 0.01) as compared with that in Group 2 (05.93 ± 0.31 U/ml). In Group 5, the level of glycogen in liver was significantly ( < 0.01) increased as compared with that in Group 2 rats. The level of antioxidant enzymes in Group 5 restored toward normal values significantly ( < 0.01; < 0.001) as compared with that in Group 2 animals. These findings suggest that low-dose combination of CREE and UA is effective in the treatment of diabetes.

摘要

( )和熊果酸(UA)是具有多种药理活性的阿育吠陀药物,包括抗糖尿病活性,但迄今为止,尚无关于它们联合使用的研究。本研究记录了 与 UA 联合在大鼠中的抗糖尿病疗效。大鼠分为六组。除正常对照组外,所有组均通过腹腔途径单次给予 50mg/kg 的链脲佐菌素(STZ)诱导糖尿病。第 1 组作为正常对照组(NC),给予生理盐水,第 2 组作为糖尿病对照组,第 3 组作为 STZ+ 乙醇提取物(CREE)组,剂量为 50mg/kg 口服,第 4 组为 STZ+UA 组,剂量为 50mg/kg 口服,第 5 组为 STZ+CREE(25mg/kg 口服)+UA(25mg/kg 口服)组,第 6 组为 STZ+格列美脲(0.1mg/kg)组。通过测定血糖水平,在 72 小时后确认糖尿病,然后在接下来的 28 天内进行治疗。在治疗过程中,每隔 7 天定期测量血浆胰岛素和血糖。在方案结束时,收集血液并处死动物。测量血糖水平、胰岛素水平、肝糖原储存水平和抗氧化酶(LPO、CAT、SOD、GPx、GST)。与第 2 组(321.75±5.46mg/dl)相比,第 5 组(13.65±0.10U/ml)的血糖水平显著(<0.001)降低至 98.35±2.45mg/dl。与第 2 组(05.93±0.31U/ml)相比,第 5 组的血浆胰岛素水平显著(<0.01)升高至 13.65±0.10U/ml。与第 2 组大鼠相比,第 5 组肝脏中糖原的水平显著(<0.01)升高。与第 2 组动物相比,第 5 组抗氧化酶水平显著(<0.01;<0.001)恢复正常。这些发现表明,CREE 和 UA 的低剂量联合使用可有效治疗糖尿病。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a4c2/7049865/6cdb946cff10/OMCL2020-8565760.001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验